NCT06323590Active, not recruiting
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study
Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot
Source: ClinicalTrials.gov · Last updated 8 May 2026
Brief summary (registry, in English)
The purpose of the study is to observe the outcomes of patients with acute myeloid leukemia who do not receive an immediate second round of chemotherapy after undergoing a standard mid-induction bone marrow biopsy.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 14 Mar 2024
- Start date
- 2 May 2024
- Primary completion date
- May 2028
- Lead sponsor
- University of Alabama at Birmingham
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT06323590
What you commit to
- Study type: Observational
- Planned participants: 60
- From 2 May 2024 to the primary completion date, May 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recipients of prior allogeneic stem cell transplant.
- Received any investigational drugs within the 14 days prior to the first day of induction
Other illness
- Any other active malignancy requiring treatment or with expected survival ≤1 year.
- Patients with psychiatric illness or social situation that would limit compliance with the study requirements.
- Patients with active CNS disease
Other
- Patients with APL
- Pregnant and/or breastfeeding
Who the study is looking for
- Adult male or female, age ≥18
- Patients with newly diagnosed AML (de novo or secondary), treated with intensive induction chemotherapy (7+3+/-3rd agent). The 3rd agent will be midostaurin for FLT3-mutant AML or gemtuzumab ozogamicin for core-binding factor AML. Patients on clinical trial with an investigational agent added to 7+3, may be enrolled on the protocol after discussion between the investigators and medical monitors.
- Prior use of hypomethylating agents, lenalidomide, erythropoiesis stimulating agents and growth factors as allowed for treatment of myelodysplastic syndrome. Prior treatment for AML is not allowed.
- Cardiac function: Ejection fraction \>50-55%
- Adequate organ function for receipt for induction chemotherapy
- Patients with HIV and Hepatitis B or C should have controlled disease.
- Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Alabama at Birmingham Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.